This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2013 Jun;27(6):1411-3.

doi: 10.1038/leu.2012.324. Epub 2012 Nov 9.

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia

O G Ottmann, R A Larson, H M Kantarjian, P D le Coutre, M Baccarani, A Hochhaus, D W Kim, X Fan, S Novick, F J Giles

PMID: 23138184
DOI: 10.1038/leu.2012.324

Clinical Trial

Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia

O G Ottmann et al. Leukemia. 2013 Jun.

. 2013 Jun;27(6):1411-3.

doi: 10.1038/leu.2012.324. Epub 2012 Nov 9.

Authors

O G Ottmann, R A Larson, H M Kantarjian, P D le Coutre, M Baccarani, A Hochhaus, D W Kim, X Fan, S Novick, F J Giles

PMID: 23138184
DOI: 10.1038/leu.2012.324

No abstract available

PubMed Disclaimer

Similar articles

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Kantarjian HM, et al. Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Lancet Oncol. 2011. PMID: 21856226 Clinical Trial.
Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.
Varda-Bloom N, Danylesko I, Shouval R, Eldror S, Lev A, Davidson J, Rosenthal E, Volchek Y, Shem-Tov N, Yerushalmi R, Shimoni A, Somech R, Nagler A. Varda-Bloom N, et al. Oncotarget. 2017 Jan 3;8(1):418-429. doi: 10.18632/oncotarget.13439. Oncotarget. 2017. PMID: 27880933 Free PMC article.
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, Inaba H, Bhojwani D, Metzger ML, Cheng C, Choi JK, Jacobsen J, Shurtleff SA, Raimondi S, Ribeiro RC, Pui CH, Campana D. Jeha S, et al. Cancer. 2014 May 15;120(10):1514-9. doi: 10.1002/cncr.28598. Epub 2014 Feb 5. Cancer. 2014. PMID: 24501014 Free PMC article.
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M. Steinberg M. Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005. Clin Ther. 2007. PMID: 18158072 Review.
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP, Paolini S, Martinelli G. Piccaluga PP, et al. Cancer. 2007 Sep 15;110(6):1178-86. doi: 10.1002/cncr.22881. Cancer. 2007. PMID: 17701954 Review.

See all similar articles

Cited by

Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia.
Shen N, Yan F, Pang J, Zhao N, Gangat N, Wu L, Bode AM, Al-Kali A, Litzow MR, Liu S. Shen N, et al. Clin Cancer Res. 2017 Oct 15;23(20):6254-6266. doi: 10.1158/1078-0432.CCR-17-0235. Epub 2017 Jul 18. Clin Cancer Res. 2017. PMID: 28720666 Free PMC article.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1^T315I and BCR-ABL1^T315I-E255K.
Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, Najib D, Chiriches C, Ottmann OG, Hantschel O, Biondi RM, Ruthardt M, Mahajna J. Mian AA, et al. Ann Hematol. 2021 Aug;100(8):2023-2029. doi: 10.1007/s00277-020-04357-z. Epub 2021 Jun 10. Ann Hematol. 2021. PMID: 34110462 Free PMC article.
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Jain N, et al. Am J Hematol. 2021 Aug 1;96(8):1000-1007. doi: 10.1002/ajh.26238. Epub 2021 May 28. Am J Hematol. 2021. PMID: 33991360 Free PMC article.
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fielding AK, Zakout GA. Fielding AK, et al. Curr Hematol Malig Rep. 2013 Jun;8(2):98-108. doi: 10.1007/s11899-013-0155-4. Curr Hematol Malig Rep. 2013. PMID: 23475624 Review.
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bernt KM, Hunger SP. Bernt KM, et al. Front Oncol. 2014 Mar 25;4:54. doi: 10.3389/fonc.2014.00054. eCollection 2014. Front Oncol. 2014. PMID: 24724051 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.